Adcetris survival data mature amid ongoing tox concerns
This article was originally published in Scrip
Executive Summary
Takeda's Millennium unit and partner Seattle Genetics have reported significant three-year survival follow-up data for their antibody-drug conjugate (ADC) product, Adcetris (brentuximab vedotin) in relapsed or refractory Hodgkin's lymphoma (HL) from its pivotal Phase II study. The data come as a boost for the product's efficacy, at least, while doubts swirl over its safety profile.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.